Dr. Farrukh Awan on Clinical Activity of Entospletinib in Patients with CLL

Video

Farrukh T. Awan, MBBS, discusses a phase II trial examining the clinical activity of entospletinib in patients with chronic lymphocytic leukemia who were previously treated with a B-cell receptor pathway signaling inhibitor.

Farrukh T. Awan, MBBS, associate professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses a phase II trial examining the clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.

Awan says treatment for CLL is rapidly evolving at this time and many patients are being exposed to kinase inhibitor treatments. He adds that when a patient fails a TKI treatment, further treatment is not well-defined. Data from the phase II trial shows that entospletinib is a well-tolerated compand in patients with CLL.

Related Videos
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content